Department of Medical Sciences, Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Department of Medical Sciences, Clinical Chemistry, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Eur J Clin Invest. 2016 Jun;46(6):501-10. doi: 10.1111/eci.12619. Epub 2016 Apr 15.
We have previously shown that older thrombus is associated with a twofold higher long-term mortality in ST-segment elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention (pPCI). We evaluated whether the addition of the presence of older thrombus to a multimarker model would result in increased predictive power for 1-year mortality in STEMI patients.
The study population (n = 1442) consists of STEMI patients treated with thrombus aspiration during pPCI. Patients were included if aspirated thrombus material could histopathologically be classified according to thrombus age (n = 870) and laboratory measurements of biomarkers (cardiac troponin T, glucose, N-terminal pro-brain natriuretic peptide, estimated glomerular filtration rate and C-reactive protein) were available. The additional prognostic value of the presence of older thrombus beyond multiple biomarkers and established clinical risk factors was evaluated using multivariate Cox regression models.
Serum biomarker concentrations were similar between patients with fresh and older thrombus. Sixty patients (7%) died within 1 year. The presence of older thrombus remained strongly associated with mortality at 1 year after multivariable adjustment for multiple biomarkers and established clinical risk factors. Addition of older thrombus to either a model including clinical risk factors and biomarkers or a model including solely biomarkers resulted in significant increases in the discriminative value, evidenced by net reclassification improvement and integrated discriminative improvement.
The presence of older thrombus provides independent complementary information to a multimarker model including established clinical risk factors and multiple biomarkers for predicting 1-year mortality in STEMI patients treated with pPCI and thrombus aspiration.
我们之前的研究表明,在接受直接经皮冠状动脉介入治疗(pPCI)的 ST 段抬高型心肌梗死(STEMI)患者中,陈旧血栓与长期死亡率增加两倍相关。我们评估了在多标志物模型中增加陈旧血栓的存在是否会导致 STEMI 患者 1 年死亡率的预测能力增加。
研究人群(n=1442)包括接受 pPCI 时进行血栓抽吸的 STEMI 患者。如果抽吸的血栓物质可以通过组织病理学分类为陈旧血栓(n=870),并且可以获得实验室测量的生物标志物(心肌肌钙蛋白 T、葡萄糖、N 末端脑利钠肽前体、估计肾小球滤过率和 C 反应蛋白),则纳入患者。使用多变量 Cox 回归模型评估陈旧血栓的存在除了多个生物标志物和已建立的临床危险因素之外的额外预后价值。
新鲜血栓和陈旧血栓患者的血清生物标志物浓度相似。60 名患者(7%)在 1 年内死亡。在对多个生物标志物和已建立的临床危险因素进行多变量调整后,陈旧血栓的存在与 1 年后的死亡率仍然密切相关。将陈旧血栓添加到包括临床危险因素和生物标志物的模型或仅包括生物标志物的模型中,均显著提高了判别值,表现为净重新分类改善和综合判别改善。
陈旧血栓的存在为包括已建立的临床危险因素和多个生物标志物的多标志物模型提供了独立的补充信息,用于预测接受 pPCI 和血栓抽吸治疗的 STEMI 患者的 1 年死亡率。